Status:
WITHDRAWN
Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
Lead Sponsor:
Vanderbilt University
Conditions:
Congenital Heart Disease
Eligibility:
All Genders
Up to 6 years
Phase:
PHASE2
Brief Summary
Phenoxybenzamine, an irreversible alpha-adrenergic blocker, may prove beneficial to infants and children with congenital heart disease undergoing open cardiac repair, due to a theoretic benefits of a ...
Detailed Description
II. Background 1. Description of the Problem One of the effects of cardiac operations involving cardiopulmonary bypass is reversible myocardial dysfunction lasting a number of days postoperatively. T...
Eligibility Criteria
Inclusion
- Patient selection will be determined by an assessment of the risk of systemic ventricular dysfunction following open cardiac repair in a population of infants undergoing stage I palliation (Norwood procedure) for the diagnosis of either hypoplastic left heart syndrome or similar left-sided obstructive lesions in the setting of single-ventricle physiology. Eligible neonates and infants include those aged 0 days to 6 months. These patients will be evaluated on an individual basis and the decision to give phenoxybenzamine would be determined by the attending surgeon, anesthesiologist, and cardiologist.
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00770705
Start Date
October 1 2008
End Date
August 1 2010
Last Update
May 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt Children's Hospital
Nashville, Tennessee, United States, 37232